Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies. The classification of Biosimilar Monoclonal Antibodies includes Infliximab, Rituximab, Trastuzumab, Adalimumab and Other, and the sales proportion of Infliximab in 2017 is about 36.5%. Market Analysis and Insights: Global Biosimilar Monoclonal Antibodies Market The global Biosimilar Monoclonal Antibodies market is valued at US$ 4574.3 million in 2019. The market size will reach US$ 25770 million by the end of 2026, growing at a CAGR of 27.7% during 2021-2026. Global Biosimilar Monoclonal Antibodies Scope and Market Size Biosimilar Monoclonal Antibodies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilar Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027. Segment by Type Infliximab Rituximab Trastuzumab Adalimumab Other Segment by Application Oncology Autoimmune Disease Other By Company Celltrion Pfizer (Hospira) 3SBIO Novartis (Sandoz) Dr Reddy's Celgen Biopharma Cadila Healthcare Hisun Pharma Torrent Pharmaceuticals By Region North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia
1 Study Coverage 1.1 Biosimilar Monoclonal Antibodies Product Introduction 1.2 Market by Type 1.2.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type 1.4.2 Infliximab 1.4.3 Rituximab 1.2.4 Trastuzumab 1.2.5 Adalimumab 1.2.6 Other 1.3 Market by Application 1.3.1 Global Biosimilar Monoclonal Antibodies Market S
